BioMarin preaches patience amid slow sales for hemophilia gene therapy

The company earned only $3.5 million last year from its Roctavian treatment, far below the $50 million to $150 million range it had forecast eight months ago.

By Ben Fidler • Feb. 23, 2024

For Moderna, COVID vaccines were a ‘proof of concept’ — now comes the big test

Following Moderna’s COVID-19 vaccine success, therapeutics head Dr. Kyle Holen discusses scaling mRNA development to bring candidates to the finish line in oncology and more.

By Amy Baxter • Feb. 23, 2024

Explore the Trendline➔

Commercialization, marketing and social media

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

By PharmaVoice staff

AbbVie CEO Richard Gonzalez leaves a divisive Humira legacy and lasting impact on pharma

Leading AbbVie to become one of the most successful pharmas in the world, Gonzalez also rubbed some critics the wrong way.

By Michael Gibney • Feb. 22, 2024

Biden or Trump: How deeply will 2024’s election outcome impact pharma?

The election is still months away, but campaign promises are solidifying, and signal the benefits and drawbacks of each candidate for pharma.

By Michael Gibney • Feb. 20, 2024

Pharma CFOs need R&D vigilance in tough economic times

Belt tightening and streamlined portfolios are critical in 2024 amid continued economic uncertainty.

By Amy Baxter • Feb. 16, 2024

The roadblocks faced by Biogen are many, but execs point to an R&D-focused turnaround

A disappointing few years for Biogen have led leadership to use new drug launches as fuel for an about-face.

By Michael Gibney • Feb. 15, 2024

‘I wish I could see the end of the day’ — a Pfizer exec on the fight for health equity

The pharma giant’s leader of a collective devoted to health equity discusses how companies can put their money where their mouth is to reach communities in need.

By Michael Gibney • Feb. 14, 2024

FDA inches closer to defining its regulatory role in AI

Commissioner Dr. Robert Califf signals how the FDA will consider AI in drug development and how the agency may use the emerging technology in the future.

By Amy Baxter • Feb. 12, 2024

Big Pharma players Amgen, Roche and Pfizer seek to follow in Novo and Lilly’s weight loss footsteps

While Novo Nordisk and Eli Lilly have a sizable lead in the quickly expanding GLP-1 market, Big Pharma peers are looking for a way in.

By Michael Gibney • Feb. 8, 2024

Why a former BMS exec calls her new CEO role ‘unfinished business’ in cancer care

With a focus on her “three pillars” of being a CEO, Caroline Loew explains how she’s building a new company culture at an Alkermes spinoff — and a pipeline that offers a next-gen approach to oncology.  

By Alexandra Pecci • Feb. 6, 2024

Vaxxinity is brewing up meds for a spacefaring future

The biotech’s bone- and muscle-building treatments could someday help humans reach other planets. 

By Kelly Bilodeau • Feb. 5, 2024

Merck keeps deal focus with Keytruda patent cliff on horizon

The company is open to deals the size of its prior Acceleron and Prometheus buyouts. “We continue to believe we need more,” CEO Rob Davis said.

By Ned Pagliarulo • Feb. 1, 2024

Pfizer’s COVID vax and antiviral sales have crashed. Will the ‘big bet’ on Seagen even the keel?

In the first earnings call since the $43 billion Seagen deal closed, CEO Albert Bourla stressed that Pfizer is all in on the promise of ADCs to make up for COVID losses.

By Michael Gibney • Feb. 1, 2024

Immunotherapy changed the cancer treatment landscape. Is the gut microbiome the next frontier?

The president of L.A.’s City of Hope Cancer Center believes the current state of cancer treatments can be greatly improved with a peek into the gut’s many mysteries.  

By Michael Gibney • Jan. 31, 2024

‘1 plus 1 equals 3’ — the co-CEO model in pharma

Amylyx Pharmaceuticals’ co-founders and co-CEOs Josh Cohen and Justin Klee explain their approach to dual leadership and why it can be a good fit in life sciences.

By Meagan Parrish • Jan. 26, 2024

The biggest questions hanging over pharma in 2024

Key trends on the horizon in the life sciences this year.

By Meagan Parrish • Jan. 25, 2024

J&J’s 2024 strategy will focus on newer meds to offset Stelara’s patent cliff

Executives on the healthcare giant’s full-year earnings call highlighted a strong cash position and incremental dealmaking as a way to get past incoming competition.

By Michael Gibney • Jan. 24, 2024

Five years after closing the Shire deal, Takeda is ready to harvest from its latest reinvention

Amid criticisms of Takeda’s megamerger, the company’s CSO said it has built a pipeline that will deliver.

By Meagan Parrish • Jan. 19, 2024

FDA chief says agency can’t manage health tech alone

FDA Commissioner Dr. Robert Califf recently spoke about the future of AI and machine learning and the need for constant vigilance to improve healthcare systems.

By Alexandra Pecci • Jan. 16, 2024

Pharma execs sound off on trends and policies they’re tracking in 2024

From regulatory concerns to leadership skills, pharma leaders at JPM shared how they’re approaching the coming year.

By Meagan Parrish • Jan. 12, 2024

10 of our most read articles in 2023

A presidential candidate, a changing biotech market and an enduring murder mystery — here are PharmaVoice’s most-read articles this year.

By Meagan Parrish • Dec. 22, 2023

Rise of the chief investment officer: Why the unique role works for Roivant

Dr. Mayukh Sukhatme, president and chief investment officer for Roivant, discusses the long game of partnering and business deals in biopharma.

By Alexandra Pecci • Dec. 18, 2023

A former CDC head on key R&D areas, public trust and if we learned anything from COVID-19

Dr. Julie Gerberding, now president and CEO of the Foundation for the National Institutes of Health, shares lessons learned from a long career in academic, public health and industry.

By Meagan Parrish • Dec. 13, 2023

Bristol Myers’ commercial chief on the industry’s ‘seismic’ changes over 27 years and what’s coming next

Adam Lenkowsky’s unique vantage point on the major transformations shaping BMS and the industry as a whole.

By Michael Gibney • Dec. 12, 2023

Real Chemistry’s CEO on biopharma’s outlook in 2024

Shankar Narayanan, CEO of marketing consulting firm Real Chemistry, weighs in on where the industry is headed in the New Year.

By Michael Gibney • Dec. 7, 2023